Insulin-like growth factor-binding proteins (IGFBPs) 1–6 bind IGFs but not insulin with high
affinity. They were initially identified as serum carriers and passive inhibitors of IGF actions …

Insulin-like growth factor binding protein-3 (IGFBP-3) is a p53 tumor suppressor-regulated
protein and a major carrier for IGFs in circulation. Among six high-affinity IGFBPs, which are …

Simple Summary Bone sarcomas are mesenchymal origin tumors. Bone sarcoma patients
show a variable response or do not respond to chemotherapy. Notably, improving efficient …

Renal cell carcinoma (RCC) incidence is highest in highly developed countries and it is the
seventh most common neoplasm diagnosed. RCC management include nephrectomy and …

Insulinlike growth factor (IGF) binding proteins (IGFBPs) 1 to 6 are high-affinity regulators of
IGF activity. They generally inhibit IGF actions by preventing binding to the IGF-I receptor but …

Purpose For the vast majority of ovarian cancer patients, optimal surgical debulking remains
a key prognostic factor associated with improved survival. A standardized, biomarker‐based …

Exposure to inorganic arsenic (As), a carcinogen and epigenetic toxicant, has been
associated with lower circulating levels of insulin-like growth factor 1 (IGF1) and impaired …

Background & Aims Transforming growth factor (TGF-β)–induced activation of quiescent
hepatic stellate cells (HSCs) and their transformation to myofibroblasts is a key event in liver …

Background IGF‐binding protein 3 (IGFBP‐3) has previously been identified as tumor
marker. The present study aimed to investigate the clinical significance of serum IGFBP‐3 in …

Aims Insulin-like growth factor (IGF) signaling has been documented in several human
malignancies and is thought to contribute to cellular differentiation and migration, as well as …